Hims & Hers reported mixed Q2 results, missing EPS estimates but exceeding revenue expectations and raising its full-year 2026 revenue guidance. Despite the strong revenue performance and increased outlook, the significant EPS miss led to a post-market stock drop, indicating investor concern over profitability.
Hims & Hers Health Inc. (HIMS) released its Q2 2026 earnings, showing a substantial miss on EPS (-$0.37 vs. -$0.03 consensus) but a beat on revenue ($753.21M vs. $699.889M). The company also raised its fiscal 2026 revenue outlook to $3.1B-$3.3B, exceeding analyst estimates. Despite the positive revenue growth and optimistic forward guidance, the significant earnings per share miss appears to be the primary driver of the stock's 5.61% drop in extended trading. This suggests that while growth is strong, profitability concerns are weighing heavily on investors, potentially leading to short-term negative pressure on HIMS shares, even with long-term growth prospects remaining intact.